Hu, W.; Zhang, L.; Ferri-Borgogno, S.; Kwan, S.-Y.; Lewis, K.E.; Cun, H.T.; Yeung, T.-L.; Soliman, P.T.; Tarapore, R.S.; Allen, J.E.;
et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436.
https://doi.org/10.3390/cancers12092436
AMA Style
Hu W, Zhang L, Ferri-Borgogno S, Kwan S-Y, Lewis KE, Cun HT, Yeung T-L, Soliman PT, Tarapore RS, Allen JE,
et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers. 2020; 12(9):2436.
https://doi.org/10.3390/cancers12092436
Chicago/Turabian Style
Hu, Wen, Li Zhang, Sammy Ferri-Borgogno, Suet-Ying Kwan, Kelsey E. Lewis, Han T. Cun, Tsz-Lun Yeung, Pamela T. Soliman, Rohinton S. Tarapore, Joshua E. Allen,
and et al. 2020. "Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype" Cancers 12, no. 9: 2436.
https://doi.org/10.3390/cancers12092436
APA Style
Hu, W., Zhang, L., Ferri-Borgogno, S., Kwan, S.-Y., Lewis, K. E., Cun, H. T., Yeung, T.-L., Soliman, P. T., Tarapore, R. S., Allen, J. E., Guan, X., Lu, K. H., Mok, S. C., & Au-Yeung, C.-L.
(2020). Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers, 12(9), 2436.
https://doi.org/10.3390/cancers12092436